Phenylephrine/ketorolac
Combination drug used during eye surgery
From Wikipedia, the free encyclopedia
Phenylephrine/ketorolac, sold under the brand name Omidria, is a combination drug used during cataract surgery[3] or intraocular lens replacement to prevent intraoperative miosis and to reduce postoperative pain.[1] It contains phenylephrine and ketorolac.[1]
Trade namesOmidria
| Combination of | |
|---|---|
| Phenylephrine | Alpha-1 adrenergic receptor agonist |
| Ketorolac | Nonsteroidal anti-inflammatory |
| Clinical data | |
| Trade names | Omidria |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intraocular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Phenylephrine/ketorolac was approved for medical use in the United States in May 2014,[4] and in the European Union in July 2015.[2]
